MedPath

Avicenna.AI's CINA-CSpine AI Tool Receives FDA 510(k) Clearance for Cervical Spine Fracture Detection

• Avicenna.AI has received FDA 510(k) clearance for its CINA-CSpine tool, designed to detect and assess cervical spine fractures using AI. • The CINA-CSpine tool utilizes deep learning and machine learning algorithms to analyze CT imaging for cervical spine fractures. • The AI tool aims to reduce the time between scan and interpretation, which is crucial for the effective treatment of cervical spine fractures.

Avicenna.AI has announced that its CINA-CSpine tool has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This AI-powered tool is designed to detect and assess cervical spine fractures using deep learning and machine learning algorithms on CT imaging. The clearance marks a significant step forward in the application of artificial intelligence in diagnostic radiology, potentially improving the speed and accuracy of fracture detection.
The CINA-CSpine tool analyzes CT scans to identify potential cervical spine fractures, which are serious injuries that require prompt and accurate diagnosis, especially when the spinal cord is involved. According to Avicenna.AI, the tool aims to reduce the delay between scan acquisition and interpretation, a critical factor in the effective treatment of this condition.

AI to Expedite Diagnosis

Cyril Di Grandi, co-founder and CEO of Avicenna.AI, emphasized the importance of timely diagnosis in managing cervical spine fractures. "Cervical spine fractures are serious injuries that require prompt and appropriate medical attention, especially if the spinal cord is involved, so accurate diagnosis is essential," he stated. "With CINA-CSpine, we aim to help reduce the delay between scan and interpretation, which is critical in the treatment of this condition."
The CINA-CSpine tool integrates advanced AI algorithms to assist radiologists and other healthcare professionals in identifying and assessing cervical spine fractures. By quickly analyzing CT scans, the tool can help prioritize cases and ensure that patients receive timely medical attention.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves AI Tool icobrain aria for Detecting ARIA in Alzheimer's Immunotherapy Patients

The FDA has approved icobrain aria, an AI-driven software, to assist in detecting ARIA (Amyloid-Related Imaging Abnormalities) in MRI scans of patients undergoing amyloid immunotherapy.
Clinical studies showed that radiologists using icobrain aria improved their sensitivity in detecting ARIA-E from 71% to 87% and ARIA-H from 69% to 79%.

FDA Clears AI-Driven MRI Tool icobrain aria for Safer Alzheimer's Treatment

The FDA has cleared icobrain aria, the first AI software for detecting and grading amyloid-related imaging abnormalities (ARIA) linked to Alzheimer's therapies.
Clinical studies showed icobrain aria significantly improves radiologists' accuracy in ARIA assessment, enhancing the safety of amyloid-targeting treatments.

FDA Approves AI Tool for ARIA Detection, Expands Nerivio Indication, and Grants Accelerated Approval to Gene Therapy for AADC Deficiency

The FDA cleared icobrain aria, the first AI software to detect and grade amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease, enhancing patient safety during anti-amyloid treatments.
Theranica's Nerivio receives expanded FDA approval for acute migraine treatment in patients aged 8 and older, offering a needle-free, non-drug alternative for pediatric migraine.

icometrix's AI-Powered icobrain aria Receives FDA Clearance for ARIA Detection

icometrix's icobrain aria, an AI-driven MRI solution, has received FDA clearance for detecting amyloid-related imaging abnormalities (ARIA).
The AI software improves the accuracy of ARIA assessments, a potential side effect of amyloid-targeting therapies for Alzheimer's disease.

FDA Clears Icobrain Aria: AI Tool for Enhanced ARIA Detection in Alzheimer's Treatments

The FDA has cleared Icobrain Aria, the first AI software for detecting and grading amyloid-related imaging abnormalities (ARIA) associated with Alzheimer's treatments.
Icobrain Aria uses brain MRI scans to generate a quantitative report, including severity scores for ARIA-edema and ARIA-hemorrhages, integrated into hospital workflows.

FDA Authorizes AI-Driven MRI Solution Icobrain Aria for Safer Alzheimer's Treatment

The FDA has cleared Icometrix's Icobrain Aria, the first AI software for detecting and monitoring amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients.
Icobrain Aria improves the accuracy of ARIA assessments by radiologists, enhancing the safety of amyloid-targeting therapies for Alzheimer's disease.

Acuitive Technologies' CITREPORE Receives FDA Clearance as Novel Bone Void Filler

Acuitive Technologies secured FDA 510(k) clearance for CITREPORE, a synthetic bioactive bone void filler utilizing CITREGEN® technology, designed for orthopedic procedures.
CITREPORE is engineered to resorb predictably, facilitating bone regeneration by releasing citrate, which enhances bone metabolism and formation during the healing process.

FDA Clears AI Tool AutoChamber for Detecting Heart Disease Risk on Chest CT Scans

The FDA has cleared HeartLung Technologies' AutoChamber, an AI tool that identifies cardiovascular risk factors from standard chest CT scans, including those performed for lung cancer screening.
AutoChamber analyzes CT scans to evaluate the risk of heart failure, atrial fibrillation, and stroke, conditions often unreported in current CT scan analyses.

AccurKardia and iCardio.ai Advance AI-Powered Cardiac Screening with FDA Designations

AccurKardia received FDA Breakthrough Device designation for its AI-driven ECG software designed to detect aortic valve stenosis (AVS) using existing ECG data.
iCardio.ai obtained FDA 510(k) clearance for its AI software, EchoMeasure, which automates echocardiographic interpretation and streamlines imaging workflows.

FDA Clears New PET Imaging Tools for Enhanced Alzheimer's Diagnosis and Monitoring

Siemens Healthineers' syngo.PET Cortical Analysis software gains FDA clearance for Centiloid scoring and tau PET quantification, enhancing Alzheimer's disease assessment.
Centiloid scoring standardizes amyloid plaque quantification across different PET scans, crucial for accurate diagnosis and monitoring of amyloid-targeting therapies.

Reference News

[1]
Avicenna.AI receives FDA 510(k) clearance for cervical spine fracture AI tool - Healio
healio.com · Sep 29, 2024

Avicenna.AI received FDA 510(k) clearance for its CINA-CSpine tool, which uses AI to detect and assess cervical spine fr...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy